Anti-cancer activity; Carbamates; Heterocyclic amines; Melampomagnolide B; Parthenolide; antileukemic agent; antineoplastic agent; carbamic acid derivative; melampomagnolide b; reactive oxygen metabolite; unclassified drug; [1alpha methyl 8 methylene 9 oxo 1alpha,2,3,6,7, 7alpha,8,9,10alpha,10beta decahydrooxirenol(2',3':9,10)cyclodecal[1,2 b]furan 5 yl]methyl (3 morpholinopropyl)carbamate; [1alpha methyl 8 methylene 9 oxo 1alpha,2,3,6,7, 7alpha,8,9,10alpha,10beta decahydrooxirenol(2',3':9,10)cyclodecal[1,2 b]furan 5 yl]methyl [3 (1h imidazol 1 yl)propyl]carbamate; [1alpha methyl 8 methylene 9 oxo 1alpha,2,3,6,7, 7alpha,8,9,10alpha,10beta decahydrooxirenol(2',3':9,10)cyclodecal[1,2 b]furan 5 yl]methyl [5 (methylthio) 1h 1,2,4 triazol 3 yl]carbamate; [1alpha methyl 8 methylene 9 oxo 1alpha,2,3,6,7, 7alpha,8,9,10alpha,10beta decahydrooxirenol[2',3':9,10]cyclodecal[1,2 b]furan 5 yl]methyl 4,4 difluoropiperidine 1 carboxylate; [1alpha methyl 8 methylene 9 oxo 1alpha,2,3,6,7, 7alpha,8,9,10alpha,10beta decahydrooxirenol[2',3':9,10]cyclodecal[1,2 b]furan 5 yl]methyl [2 (pyridin 2 yl)ethyl]carbamate; [1alpha methyl 8 methylene 9 oxo 1alpha,2,3,6,7, 7alpha,8,9,10alpha,10beta decahydrooxirenol[2',3':9,10]cyclodecal[1,2 b]furan 5 yl]methyl [2 (pyrrolidin 1 yl)ethyl]carbamate; [1alpha methyl 8 methylene 9 oxo 1alpha,2,3,6,7, 7alpha,8,9,10alpha,10beta decahydrooxirenol[2',3':9,10]cyclodecal[1,2 b]furan 5 yl]methyl [2 morpholino ethyl]carbamate; antineoplastic agent; carbamic acid derivative; melampomagnolide B; sesquiterpene; antineoplastic agent; carbamic acid derivative; hydroxyl group; melampomagnolide b; parthenolide; antineoplastic activity; apoptosis; article; breast cancer; breast cancer cell line; cancer cell; cancer inhibition; carbon nuclear magnetic resonance; central nervous system tumor; colon cancer; controlled study; drug half life; drug synthesis; human; human cell; kidney cancer; leukemia; leukemia cell line; lung cancer; lung cancer cell line; lung non small cell cancer; melanoma; Michael addition; nuclear magnetic resonance; ovary cancer; oxidative stress; prostate cancer; renal cancer cell line; structure activity relation; cell proliferation; chemical structure; chemistry; dose response; drug effects; drug screening; synthesis; Tanacetum parthenium; tumor cell line; Article; biological activity; cancer cell line; non small cell lung cancer; Antineoplastic Agents, Phytogenic; Carbamates; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Sesquiterpenes; Structure-Activity Relationship; Tanacetum parthenium